Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1979 1
1980 4
1981 3
1982 8
1983 19
1984 10
1985 9
1986 18
1987 17
1988 27
1989 30
1990 47
1991 56
1992 81
1993 81
1994 72
1995 106
1996 139
1997 130
1998 121
1999 118
2000 123
2001 145
2002 116
2003 141
2004 122
2005 121
2006 121
2007 113
2008 109
2009 105
2010 106
2011 83
2012 94
2013 70
2014 83
2015 86
2016 74
2017 62
2018 63
2019 67
2020 74
2021 122
2022 11
Text availability
Article attribute
Article type
Publication date

Search Results

3,114 results
Results by year
Filters applied: . Clear all
Page 1
Fluvoxamine.
[No authors listed] [No authors listed] 2021 Oct 18. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. 2021 Oct 18. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. PMID: 30000246 Free Books & Documents. Review.
If fluvoxamine is required by the mother, it is not a reason to discontinue breastfeeding. A safety scoring system finds fluvoxamine use to be possible during breastfeeding.[1] One infant was reported to have an elevated serum level of fluvoxamine, but most w …
If fluvoxamine is required by the mother, it is not a reason to discontinue breastfeeding. A safety scoring system finds fluvoxami …
Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders.
Altamura AC, Caldiroli A, Buoli M. Altamura AC, et al. Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):649-60. doi: 10.1517/17425255.2015.1021331. Epub 2015 Mar 1. Expert Opin Drug Metab Toxicol. 2015. PMID: 25728382 Review.
INTRODUCTION: Fluvoxamine is one of the most widely prescribed antidepressants and presents data from 30 years of clinical experience. AREAS COVERED: The present review article describes the pharmacokinetic properties of fluvoxamine and their implications for the tr …
INTRODUCTION: Fluvoxamine is one of the most widely prescribed antidepressants and presents data from 30 years of clinical experience …
Overview of the pharmacokinetics of fluvoxamine.
van Harten J. van Harten J. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. doi: 10.2165/00003088-199500291-00003. Clin Pharmacokinet. 1995. PMID: 8846617 Review.
Fluvoxamine undergoes extensive oxidative metabolism, most probably in the liver. ...Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs. Fluvoxamine pharmacokinetics are substantially unaltered by increased age or renal impai …
Fluvoxamine undergoes extensive oxidative metabolism, most probably in the liver. ...Plasma protein binding of fluvoxamine (77 …
Clinical pharmacokinetics of fluvoxamine.
Perucca E, Gatti G, Spina E. Perucca E, et al. Clin Pharmacokinet. 1994 Sep;27(3):175-90. doi: 10.2165/00003088-199427030-00002. Clin Pharmacokinet. 1994. PMID: 7988100 Review.
Fluvoxamine is a selective inhibitor of serotonin reuptake that is widely used in the management of depression. ...Despite complete absorption, oral bioavailability may be incomplete probably because of first-pass metabolism. Approximately 77% of fluvoxamine is plas …
Fluvoxamine is a selective inhibitor of serotonin reuptake that is widely used in the management of depression. ...Despite complete a …
Fluvoxamine. A review of global drug-drug interaction data.
Wagner W, Vause EW. Wagner W, et al. Clin Pharmacokinet. 1995;29 Suppl 1:26-31; discussion 31-2. doi: 10.2165/00003088-199500291-00006. Clin Pharmacokinet. 1995. PMID: 8846620 Review.
One involved a female patient who was given concomitant tryptophan and reportedly developed neuroleptic malignant syndrome. The causative role of fluvoxamine/tryptophan interaction in this case is unknown. The other reported death was considered to be unrelated to fluvo …
One involved a female patient who was given concomitant tryptophan and reportedly developed neuroleptic malignant syndrome. The causative ro …
The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review.
Polcwiartek C, Nielsen J. Polcwiartek C, et al. Psychopharmacology (Berl). 2016 Mar;233(5):741-50. doi: 10.1007/s00213-015-4161-1. Epub 2015 Dec 2. Psychopharmacology (Berl). 2016. PMID: 26626327 Review.
OBJECTIVES: This study aims to review all pharmacodynamic effects and the adverse effect profile of changing the clozapine/NDMC ratio with adjunctive fluvoxamine. METHODS: MEDLINE, Embase, and the Cochrane Library were searched with the search terms "clozapine" and "flu …
OBJECTIVES: This study aims to review all pharmacodynamic effects and the adverse effect profile of changing the clozapine/NDMC ratio with a …
Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
Cheer SM, Figgitt DP. Cheer SM, et al. CNS Drugs. 2002;16(2):139-44. doi: 10.2165/00023210-200216020-00006. CNS Drugs. 2002. PMID: 11825104 Review.
However, steady-state plasma fluvoxamine concentrations were 2 to 3 times higher in children (aged between 6 and 11 years) than in adolescents; thus, the maximum fluvoxamine dosage recommended for children is 200 mg/day. ...Reductions in symptoms of anxiety with …
However, steady-state plasma fluvoxamine concentrations were 2 to 3 times higher in children (aged between 6 and 11 years) than in ad …
Fluvoxamine for COVID-19?
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 May 3;63(1623):69-70. Med Lett Drugs Ther. 2021. PMID: 33976099 No abstract available.
[Addition of fluvoxamine to clozapine: theory and practice].
Wigard ME, van Gool AR, Schulte PF. Wigard ME, et al. Tijdschr Psychiatr. 2013;55(2):113-21. Tijdschr Psychiatr. 2013. PMID: 23408363 Free article. Review. Dutch.
BACKGROUND: The addition of fluvoxamine to clozapine induces a rise of plasma concentrations of clozapine. ...CONCLUSION: Addition of fluvoxamine to clozapine can lead to a dangerous rise of clozapine plasma concentrations. ...
BACKGROUND: The addition of fluvoxamine to clozapine induces a rise of plasma concentrations of clozapine. ...CONCLUSION: Addition of …
[Cardioprotective effect of fluvoxamine, sigma-1 receptor high affinity agonist].
Tagashira H, Fukunaga K. Tagashira H, et al. Yakugaku Zasshi. 2012;132(2):167-72. doi: 10.1248/yakushi.132.167. Yakugaku Zasshi. 2012. PMID: 22293694 Free article. Review. Japanese.
To confirm the cardioprotective role of Sig-1R stimulation by fluvoxamine, we treated mice with fluvoxamine (0.5 or 1 mg/kg) orally once a day for 4 weeks after onset of aortic banding. ...Fluvoxamine also attenuated hypertrophy-induced impaired LV fractional …
To confirm the cardioprotective role of Sig-1R stimulation by fluvoxamine, we treated mice with fluvoxamine (0.5 or 1 mg/kg) o …
3,114 results